Who are RLD2101's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Brenzavvy, Jardiance, Empagliflozin + Carvedilol, Dapagliflozin+ACEI treatment, Antihyperglycemic Medication, Insulin/Canaglifozin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rld2101.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

RLD2101 — Competitive Intelligence Brief

RLD2101 (RLD2101) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SGLT2 inhibitor. Area: Diabetes.

phase 3 SGLT2 inhibitor SGLT2 Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

RLD2101 (RLD2101) — Hanmi Pharmaceutical Company Limited. RLD2101 is a small molecule that targets the SGLT2 receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
RLD2101 TARGET	RLD2101	Hanmi Pharmaceutical Company Limited	phase 3	SGLT2 inhibitor	SGLT2
Brenzavvy	BEXAGLIFLOZIN	Theracosbio	marketed	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	SGLT2	2023-01-01
Jardiance	empagliflozin	Boehringer Ingelheim	marketed	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	SGLT2	2014-01-01
Empagliflozin + Carvedilol	Empagliflozin + Carvedilol	Post Graduate Institute of Medical Education and Research, Chandigarh	marketed	SGLT2 inhibitor + non-selective beta-blocker combination	SGLT2 and beta-adrenergic receptors (β1, β2, α1)
Dapagliflozin+ACEI treatment	Dapagliflozin+ACEI treatment	Children's Hospital of Fudan University	marketed	SGLT2 inhibitor + ACE inhibitor combination	SGLT2 and ACE
Antihyperglycemic Medication	Antihyperglycemic Medication	Merck Sharp & Dohme LLC	marketed	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)
Insulin/Canaglifozin	Insulin/Canaglifozin	University of Campania Luigi Vanvitelli	marketed	Insulin + SGLT2 inhibitor combination	Insulin receptor; SGLT2 (sodium-glucose cotransporter 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SGLT2 inhibitor class)

Daewon Pharmaceutical Co., Ltd. · 13 drugs in this class
Qilu Pharmaceutical Co., Ltd. · 10 drugs in this class
Takeda · 10 drugs in this class
Taejoon Pharmaceutical Co., Ltd. · 9 drugs in this class
Hanmi Pharmaceutical Company Limited · 9 drugs in this class
Addpharma Inc. · 9 drugs in this class
GlaxoSmithKline · 7 drugs in this class
AO GENERIUM · 7 drugs in this class
Merck Sharp & Dohme LLC · 7 drugs in this class
Nobelpharma · 6 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RLD2101 — Competitive Intelligence Brief. https://druglandscape.com/ci/rld2101. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab